Harrow projects $71M-$81M Q2 revenue while reaffirming $350M-$365M 2026 outlook
Harrow, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $34.11
+14% in 7d after detection
Post-detection moves
1h
—
1d
+2.7%
3d
+7.5%
7d
+14%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS